Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-25-000657
Filing Date
2025-07-09
Accepted
2025-07-09 20:06:12
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18179
2 JOINT FILING AGREEMENT ss5060461_ex9901.htm EX-99.1 7295
  Complete submission text file 0000947871-25-000657.txt   27227
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SCHEDULE 13D/A

Mailing Address ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103
Business Address ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103 2678660312
Passage BIO, Inc. (Subject) CIK: 0001787297 (see all company filings)

EIN.: 822729751 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91451 | Film No.: 251114619
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)